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Abstract 
A miniaturized implantable rapid drug delivery device based on micro-
electro-mechanical-systems technology was recently developed and 
characterized.  This device is intended to address acute conditions in 
high-risk subjects.  This work provides an in vivo proof-of-concept for 
the device in a rabbit model, by releasing a physiologically active dose 
of vasopressin, a vasoconstrictor.  The devices were implanted 
subcutaneously and activated to rapidly release vasopressin, with 
monitoring of mean arterial pressure and plasma levels. 
Device releases showed a rapid and measurable effect on mean arterial 
pressure as well as a continuous diffusion of vasopressin into the 
bloodstream, consistent with a depot effect. Plasma levels in rabbits 
receiving vasopressin with the device rose monotonically to 24.4 ± 2.9 
ng/mL after one hour.  Bioavailability after one hour was calculated to 
be 6.2 ± 2.8 % (mean ± s.d.). 
A new modality for rapid and controlled drug delivery has been 
developed. The device can be used as a new implantable device 
controlled by medical algorithms (based on heart rate or mean arterial 
pressure, for example) for autonomous operation in high-risk 
populations that require immediate ambulatory intervention. 
Keywords: Subcutaneous drug delivery; vasopressin; MEMS; rabbit; 
bioavailability. 
Introduction 
MEMS technology has allowed the 
implementation of implantable drug delivery 
systems for applications that typically require 
sustained plasma drug levels for treatment of 
chronic illnesses.  A number of implantable drug 
delivery devices have been investigated for use in 
chronic and non-chronic diseases in ambulatory 
settings without medical intervention, such as 
cancer, diabetes and osteoporosis[1-4].  Drug 
delivery devices characterized by multiple-
reservoir architectures and based on electrical 
actuation mechanisms, for example, provide a 
reliable platform because of the reproducibility of 
MEMS technology. These devices typically rely  
 
on electro-thermal actuation to rupture a 
reservoir-sealing membrane as a result of an 
applied electrical potential, allowing the drugs 
inside the reservoirs to freely diffuse into the 
region of interest[2,5].  Such implantable devices 
provide a significant improvement in the 
bioavailability of drugs with poor oral 
bioavailability and alleviate problems linked to 
patient compliance.  Their use is however limited 
to treatment of chronic illnesses as they rely on 
diffusion and small delivery volumes, with 
complete drug release achieved in the range of 
hours to days. 
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The Implantable Rapid Drug Delivery Device 
(IRD3) was previously reported in vitro to deliver 
a volume of 20 µL in 45 seconds[6].  The 
delivery mechanism relies on the rapid creation 
and expansion of vapor bubbles within the device 
to force the drug solution out of the device.  This 
mechanism is similar to thermo-pneumatic 
micropumps, with an important difference.  
Thermo-pneumatic micropumps typically achieve 
pumping by displacing an elastic membrane 
against the fluid to be delivered.  Expansion and 
cooling of a gas or fluid in a separate chamber is 
achieved through microresistors [7-9].  The flow 
rate can be controlled by modulating the voltage 
applied to the microresistors and the duty cycle, 
typically reaching a few microliters per minute.  
The IRD3 is characterized by its small size and a 
faster actuation mechanism, allowing rapid drug 
release.  This device is of particular importance 
for emergency therapies requiring immediate 
drug delivery in high-risk patients who suffer 
from conditions with life-threatening acute 
symptoms. 
 
Vasopressin is a peptide found in most mammals.  
It serves two specific purposes: the modulation of 
water retention in the kidneys in response to 
increased osmolality in the blood, and at higher 
concentrations, the vasoconstriction of arterioles 
to raise blood pressure in the event of 
hypotension caused by hemorrhage[10-13].  It 
was chosen as the model drug because it is 
widely used as vasoconstrictor in cardiac 
arrest[14,15] and shows promise in the treatment 
of hemorrhagic shock[16-19].   It is thus a 
candidate for release from our device in this time-
sensitive context.   
 
One potential application of this device with 
vasopressin is the ambulatory treatment of 
wounded soldiers at risk for hemorrhagic shock.  
The device would be preventatively implanted in 
a soldier before leaving for the front.  The 
triggering of this device would be controlled by a 
medical algorithm evaluating blood pressure and 
heart rate against pre-defined thresholds.   This 
data would be obtained from standard wearable 
sensors.  Hostile conditions can delay medical 
treatment on a battlefield and evacuation 
conditions are often less than ideal to administer 
therapy by injection, but in the case of 
hemorrhagic shock, the window of opportunity 
for treatment can be on the order of minutes.  A 
subcutaneous device triggered automatically or 
remotely to deliver a dose of vasopressin could 
help sustain a soldier’s blood pressure during 
transportation, delaying the onset of hemorrhagic 
shock until proper medical treatment can be 
administered in more controlled conditions, e.g., 
a field hospital. 
 
The objective of this work was to demonstrate in 
vivo operation of the IRD3 by releasing a 
physiologically active dose of vasopressin and 
measuring its effects on blood pressure in rabbits.  
This would provide a proof of concept for in vivo 
rapid drug delivery from an implantable device. 
 
Material & Methods 
Vasopressin and Devices 
Arginine vasopressin acetate powder (Sigma-
Aldrich, Saint-Louis, MO) was reconstituted with 
sterile water to appropriate concentration for 
injection or device loading.  Device fabrication 
and drug loading have been extensively described 
previously[6]. 
 
Animal Study 
This study was approved by MIT’s Committee on 
Animal Care and the Animal Care and Use 
Review Office from the Department of Defense 
Medical Research and Material Command.  
Sixteen male New Zealand White rabbits with 
weights between 2.5 kg and 3.5 kg were obtained 
(Covance Research Products, PA, USA). The 
animals were housed in compliance with MIT’s 
Committee on Animal Care husbandry 
guidelines, with unrestricted access to water and 
food. 
 
Rabbits were anesthetized with an initial dose of 
midazolam (2 mg/kg, IV) and were maintained 
under anesthesia by mask with 1-3% isoflurane in 
balance oxygen.  The central auricular arteries in 
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both ears were catheterized for mean arterial 
pressure (MAP) monitoring and blood sampling, 
respectively.  MAP was monitored continuously 
by direct blood pressure measurement from an 
arterial catheter in the central auricular artery 
using a blood pressure sensor (Blood Pressure 
AnalyzerTM 400, Micro-Med, Louisville, KY), 
and recorded with the DMSI Software (Micro-
Med).  Values were measured every 0.5 seconds 
and averaged over 10 seconds to yield a single 
data point. 
 
The rabbits were randomly assigned to receive 
100 µg/(kg body weight) vasopressin 
subcutaneously (1 mL, conc. 0.25-0.35 mg/mL, 
Control group, n = 5), an IRD3 containing 20 µL 
of solution with the same total dose of 100 µg/(kg 
body weight) vasopressin (conc. 12.5-17.5 
mg/mL, Device group, n = 3), a subcutaneous 
injection of 1 mL water (Placebo Injection group, 
n = 4), or an IRD3 containing 20 µL of sterile 
water (Placebo Device group, n = 4).  The 
devices were implanted subcutaneously and 
activated immediately after connection to the 
external power source. 
 
 
Figure 1: Schematic representation of the experimental 
procedure.   
A device, 9 mm (L) x 6 mm (W) x 3 mm (H), is implanted 
subcutaneously and connected to an external power source.  
Activation of the device forces the drug solution out of the 
device. 
Figure 1 shows a schematic overview of the 
experiment.  A 1-cm skin incision was made 
across the left triceps of the anesthetized rabbit, 
approximately 2 cm from the elbow.  A 
subcutaneous pocket was created by blunt 
dissection over the triceps.  The device was 
introduced into the pocket through the incision, 
with the drug exit side facing the muscle.  
Biocompatible Teflon-sheathed electrical leads 
were used to connect the microheaters to the 
external power source through the incision.  
Devices were activated by applying 9 V to the 
microheaters for 10 seconds, followed by a 15 
second pause and ten 5-second applications of 9V 
with 5-second intervals, in order to minimize heat 
exposure to the animal and drug degradation due 
to activations.  Membrane rupture was monitored 
by measuring the resistance of a metallic line 
patterned over the membrane for circuit opening.   
Injections were performed at the same 
subcutaneous location where a device would be 
implanted, and the solution was injected over a 
period of approximately 2 seconds, as would be 
done in standard clinical practice.  MAP was 
continuously monitored for 1 hour following 
injection or activation.  The animals were 
euthanized at the end of the monitoring period. 
 
MAP Data Extraction 
MAP data was normalized to the starting pressure 
by subtracting the average MAP during the 5 
minutes preceding the injection or device 
activation.  The normalized data (ΔMAP) for 
each animal receiving vasopressin was analyzed 
(Excel 2003, Microsoft, Inc., USA) to extract the 
maximum ΔMAP (ΔMAPmax), the time needed to 
reach that maximum (tmax), and the time at which 
ΔMAP returned to less than zero for at least 1 
minute thereafter (tdur).  The normalized data for 
each animal in a placebo group was analyzed to 
extract ΔMAPmax only.  This number represents 
the maximum random positive fluctuation in 
MAP experienced during the monitoring period.  
There is thus no meaning in the values of tmax and 
tdur for the placebo groups. 
 
Plasma Levels and Bioavailability of 
Vasopressin 
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Three rabbits in the Control and Device groups 
received solutions containing 3H-radiolabeled 
vasopressin (American Radiolabeled Chemicals, 
St. Louis, MO).  One blood sample was collected 
before injection as control and up to 7 samples 
after injection at chosen time points up to 1 hour.   
 
The drawn blood samples were collected into BD 
Vacutainer® tubes coated with sodium heparin 
(VWR, West Chester PA) and immediately 
refrigerated for further processing.  Samples 
collected within one day were centrifuged at the 
end of each day to collect plasma.  Plasma 
samples were then processed per the 
manufacturer’s instructions using SOLVABLETM 
(PerkinElmer, Waltham, MA) and counted in a 
liquid scintillation counter (Packard Tri-Carb 
2200CA, PerkinElmer, Waltham, MA) to 
determine plasma levels.  
 
The bioavailability F of a drug delivered by an 
experimental route or formulation is expressed 
by: 
    exp
exp
DoseAUC
DoseAUC
F
ref
ref
∗
∗=
 (Eq. 1) 
 
AUC is defined as the area under the plasma level 
versus time curve of the tested drug using the 
trapezoidal rule, up to the last collected data point 
[20].  The reference sample is generally an 
intravenous dose of the drug, as it allows all of 
the injected drug to be exposed to the body.  Each 
AUC is normalized by the given dose for 
comparison.  AUC was computed for each animal 
and averaged within each group (n = 3 for each 
group).  The reference sample consisted of three 
animals that were given an intravenous injection 
of vasopressin.  The AUC for each reference 
animal was also computed and the three values 
were averaged together to yield AUCref (data not 
shown).  The bioavailability after one hour for the 
Control and Device groups was then calculated 
using Equation 1. 
 
Statistics 
Extracted values for each group were analyzed 
for statistical significance with Student’s t-test.  
A p-value lower than 0.05 was considered to be 
statistically significant.  The ΔMAPmax of each 
vasopressin group was compared to its 
corresponding placebo group, in order to evaluate 
whether the changes happening after vasopressin 
delivery were solely due to random fluctuations 
in MAP.  Additional comparisons were made at 
salient time points to contrast the Control and 
Device groups with each other and with their 
respective placebo groups. 
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Figure 2: Average ΔMAP profile for all groups.  
(a) Control (n = 5), (b) Placebo Injection (n = 4), (c) Device 
(n = 3), and (d) Placebo Device (n = 4).  Dotted lines 
represent ± 1 standard deviation. 
 
Results 
Figure 2 shows averaged ΔMAP profiles depicted 
in bold and their standard deviations in dotted 
lines.  Figure 2(a) presents the profile for the 
Control group, showing an immediate increase in 
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MAP to reach a maximum after 14 minutes, 
followed by a steady decrease to baseline at t = 
35 minutes.  Figure 2(b) shows the profile for the 
Placebo Injection group, which presents no 
feature, beside random fluctuations.  A t-test 
between the two groups at t = 14 minutes yielded 
a p-value of 0.02, suggesting the effect on MAP 
from vasopressin injection was significantly 
greater than from the water injection.  Figure 2(c) 
shows the results for the Device group.  All 
devices opened within 10 seconds after the start 
of activation.  The MAP reaches a peak in 4 
minutes, followed by a significant return to 
baseline (> 1 minute) at t = 35 minutes.  This 
decrease is not monotonic, however.  Smaller 
peaks are experienced at t = 24 and 32 minutes.  
There is also a slight dip in MAP within the first 
2 minutes.  Figure 2(d) represents the results for 
the Placebo Device group, and shows the same 
dip within the first 2 minutes, but no other 
notable feature.  A t-test at each of the peaks 
observed in Figure 2(c) (t = 4, 24 and 32 min) 
revealed that these peaks were significantly 
different from the placebo effects at their 
respective time points (p = 0.0004, 0.001 and 
0.01, respectively).   
 
Table 1: Summary of ΔMAPmax, tmax and tdur for each test 
group.  Values are reported as mean ± s.d. 
Group ΔMAPmax (mmHg) tmax (min) tdur (min) 
Control 
(n = 5) 24.3 ± 11.5 12.0 ± 4.6 39.1 ± 23.0 
Placebo 
Injection 
(n = 4) 
5.5 ± 2.3 --- --- 
Device 
(n = 3) 17.2 ± 4.2 4.0 ± 0.9 33.9 ± 6.0 
Placebo 
Device 
(n = 4) 
4.7 ± 0.7 --- --- 
 
The measured data extracted from the results is 
summarized in Table 1.  The Control and Device 
groups were found to reach a ΔMAPmax 
significantly higher than their respective placebo 
(p = 0.02 and 0.03, respectively).  This means 
that the effects observed in both vasopressin 
groups are significantly greater than could be 
observed from any random fluctuation in MAP.  
The Device and Control groups were also 
compared.  ΔMAPmax and tdur were not 
significantly different (p = 0.26 and 0.65, 
respectively), but tmax was (p = 0.02).  Further 
contrasting of the two groups using time as a 
parameter found that at t = 4.0 minutes (tmax for 
the Device group), ΔMAP was not significantly 
different (p = 0.61), but at t = 14.0 minutes (tmax 
for the Control group), ΔMAP for the Control 
group was significantly higher (p = 0.04). 
 
0
5
10
15
20
25
30
35
40
45
50
0 10 20 30 40 50 6
Va
so
pr
es
si
n 
Pl
as
m
a 
Le
ve
l 
(n
g/
m
L)
Time after Injection (min)
0
Control
Device
 
Figure 3: Vasopressin plasma levels measured by liquid 
scintillation counting. 
 
Error bars represent standard deviation.  n = 3 for both 
groups, except for the Device group where a blood sample 
could not be obtained at 15 minutes for one rabbit and at 25 
minutes for another rabbit. n = 2 at those points. 
 
Figure 3 shows measured plasma levels for the 
Control and Device groups.  Plasma levels in 
both groups rose monotonically up to one hour 
after injection or activation, but at different rates.  
Plasma levels in the Control group increased 
linearly in the first 45 minutes at a rate of 0.77 
ng/(mL-min), after which the rate of increase 
slowed down to reach a maximum concentration 
of 37.1 ± 9.2 ng/mL one hour after the injection.  
Plasma levels in the Device group initially rose to 
5.1 ± 1.3 ng/mL after 3.6 minutes, but increased 
at a slower rate of 0.35 ng/(mL-min) thereafter to 
reach a final concentration of 24.4 ± 2.9 ng/mL 
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after one hour.  Bioavailability after one hour was 
calculated to be 10.0 ± 6.3 % and 6.2 ± 2.8 % 
(mean ± s.d.) for the Control and Device groups, 
respectively. 
 
Discussion 
This work has shown that vasopressin delivered 
subcutaneously was able to quickly achieve 
plasma levels sufficient for vasoconstriction.  An 
injection of 100 g/kg resulted in an immediate 
response, as evidenced by the MAP increase 
shown in Figure 2(a).  A MEMS drug delivery 
device implanted subcutaneously was also able to 
deliver the same vasopressin dose with an 
immediately measurable effect.  The overall 
response was lower with delivery from the 
device, however, as suggested by the lower 
overall MAP profile and statistical analysis at the 
peak of the Control group.  This work 
nonetheless represents the first time to the 
authors’ knowledge that a drug released from an 
implantable drug delivery device based on 
MEMS technology achieved significant plasma 
levels with measurable physiological effects 
within this short period of time.   
 
There are a few potential causes behind the 
different MAP response of device delivery 
compared to syringe injection.  The first is an in 
vivo behavior of the devices different from in 
vitro experiments regarding released fraction and 
stability of the solution.  Previous in vitro 
experiments determined that device activation 
resulted in degradation of 9% of the released 
vasopressin [6].  Quantification of the in vivo 
degradation of vasopressin after activation was 
not feasible because of the impossibility in 
collecting the released solution in the 
subcutaneous pocket after activation.  The 
authors can only conclude that although more 
significant degradation may have happened than 
in vitro, a sufficient amount of vasopressin 
remains to affect the vascular system.  The 
activation of the device, whether thermal or 
electrical, may have also slightly affected the 
animals, exhibited as small dips in MAP 
observed with the Device and Placebo groups 
during the first 2 minutes.  The difference in the 
amount of fluid delivered (20 L vs. 1 mL) can 
also result in reduced exposure to the 
bloodstream, which may contribute to the 
observed lower bioavailability of the device 
release.  This issue, however, can be addressed by 
adjusting the delivered dose.  Finally, the rapid 
decrease in the rate of increase of vasopressin 
levels suggests that the very high concentration of 
vasopressin in the device (approximately 50 
times higher than that of an injection) may be 
subject to a rate-limiting step.  The transition 
between tissue and blood vessel may be such a 
rate-limiting step, for example, especially 
coupled with the fact that vasopressin itself 
constricts the blood vessels, further reducing the 
cross-sectional area available for diffusion. 
 
 It is not known whether the smaller peaks 
observed at t = 24 and 32 minutes are related to 
issues of degradation or diffusion.  Further 
experimentation would be needed to shed a light 
on this issue. 
 
One of the advantages of the device over syringe 
injection is made apparent by the smaller 
standard deviation of the MAP profile, even with 
a larger control sample size.  This observation 
highlights the fact that device delivery results in 
more consistent behavior than syringe injection, 
in addition to the fact that device opening was 
achieved every time within 10 seconds after 
activation.  Subcutaneous injections can be 
difficult to perform consistently, especially in 
suboptimal conditions (e.g. ambulatory settings).  
One only has to refer to the literature on 
subcutaneous administration of insulin in the 
management of diabetes to see that subcutaneous 
injections cannot ensure repeatable 
pharmacokinetics [21-23].  A device previously 
placed in the appropriate location in high-risk 
subjects will ensure repeatable and rapid delivery.  
This device can furthermore be coupled with 
receiving and triggering electronics, resulting in a 
remotely activated device, or if coupled with a 
blood pressure sensor and the appropriate 
medical algorithm, could become an autonomous 
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system, triggering automatically when blood 
pressure reaches critical levels. 
 
It has been previously reported that the 
pharmacokinetics of  vasopressin in New Zealand 
White rabbits are biexponential, reflecting two 
vasopressin elimination processes.  The faster 
process is easily saturated and has reported half-
lives between 0.6 and  0.9 minutes, while the 
slower process has reported half-lives between 5 
and 6 minutes [24].  Such short half-lives imply 
that more than 90% of intravenously injected 
vasopressin is eliminated from the bloodstream 
after 15 minutes.  Intravenous injections of 
vasopressin in rabbits (not shown) confirmed that 
the plasma levels of vasopressin fall to less than 
10% of their nominal original level 15 minutes 
after injection.  The monotonically increasing 
vasopressin levels measured in both the Control 
and Device groups for 1 hour thus indicate the 
presence of a depot effect, with vasopressin 
entering the bloodstream at a higher rate than it is 
eliminated.  It is thus counter-intuitive to see 
MAP decrease in both cases while plasma levels 
of vasopressin are still increasing.  The observed 
discrepancy between blood pressure and plasma 
level is similar to that observed by Dworkin et al, 
who reported a loss of vasoconstriction after 15 
minutes of a 30-minute infusion of vasopressin 
directly to the hepatic arterial bed in rats [25].  
Co-infusion of vasopressin with the nitric oxide 
(NO) inhibitor N(G)-nitro-L-arginine methyl 
ester (L-NAME) demonstrated that this loss of 
vasoconstriction was tied to the triggered 
production of NO, which caused vasodilation.  
The continued delivery of vasopressin in a 
healthy animal to induce forced vasoconstriction 
can conceivably be seen as a stressor, thus 
triggering a regulatory mechanism through NO 
synthesis to bring the blood pressure back to 
normal levels.  A release of vasopressin in a 
hemorrhagic shock model may show a more 
extended effect than seen in this work, because 
the vasoconstriction would be compensatory. 
An alternative explanation for the loss of 
vasoconstriction is the degradation of vasopressin 
over time, either in the blood or before entering 
the bloodstream, although it has been shown in 
vitro not to degrade in rat serum for up to 8 hours 
[26].  The radioactive method used to measure 
vasopressin levels in this work does not 
distinguish between vasopressin and its 
degradation products or metabolites.  A fraction 
of the measured plasma levels may conceivably 
correspond to degraded vasopressin or its 
metabolites that have not been filtered out by the 
kidneys.  The plasma levels and calculated 
bioavailabilities in this work therefore indicate 
maximum values.  A method such as high 
performance liquid chromatography coupled with 
mass spectroscopy (HPLC-MS) would be able to 
measure actual levels of intact vasopressin.  It 
must be emphasized, however, that regardless of 
the actual bioavailability values, the measured 
effects on MAP are real and indicate sufficient 
levels of vasopressin to induce vasoconstriction.  
Release of vasopressin in the presence of a NO 
inhibitor such as L-NAME should tip the scale 
toward one of these hypotheses, depending on 
whether it prolongs vasoconstriction in healthy 
animals.  A continuous infusion of vasopressin 
for 30 minutes or longer while monitoring MAP, 
as was done by Dworkin et al for the hepatic 
arterial bed, would also reveal whether the 
regulatory response is responsible for the 
observed behavior.   
 
Another point to address if this device is to be 
used in a hemorrhagic shock model is that the 
peripheral circulation is already reduced due to 
reduced blood volume and vasoconstriction of the 
peripheral arterioles.  Total peripheral vascular 
resistance is increased in this situation and may 
hamper the pharmacokinetics of vasopressin.  
The increasing plasma levels of vasopressin seen 
in this work despite vasoconstriction suggest that 
this may not be a problem, although the reduced 
blood volume may play a role in shock.  This 
potential issue is only valid in a hemorrhagic 
shock model.  Other conditions where peripheral 
circulation is unaffected would not encounter 
such issues. 
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This work did not address the issues of long-term 
implantation, where the formation of a fibrous 
capsule around the device may prevent diffusion 
of vasopressin.  Work by Prescott et al has shown 
that this capsule does not affect the 
pharmacokinetics of leuprolide, another 
polypeptide with similar molecular weight to 
vasopressin[2].  Long-term implantation would 
also affect the stability of vasopressin in solution.  
A dual-chamber concept for the device is being 
investigated for that purpose, where the drug is 
kept in a lyophilized form in one chamber.  The 
drug is rapidly reconstituted and released with 
water kept in a separate chamber upon activation. 
 
Conclusions 
The in vivo study presented in this work has 
provided proof of concept for the IRD3 in an 
animal model.  The lower bioavailability and 
magnitude of effects when compared to a 
subcutaneous injection are offset by better 
repeatability in the pharmacokinetic behavior and 
potential for remote or automatic delivery.  
Future development of the device may also 
increase bioavailability by reducing potential 
degradation mechanisms.  The minimum 
efficacious dose of vasopressin has not been 
determined in hemorrhagic shock, and the ability 
of the device to address it with its current dose 
should be tested in a pathological model.  Further 
research is required to address issues tied with 
long-term implantation.  Applications for the 
device could extend beyond vasopressin to 
address acute conditions treatable with other 
drugs, such as atropine or epinephrine. 
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